Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab plus chemotherapy versus bevacizumab plus chemotherapy as first-line treatment for metastatic colorectal cancer
CTR20250877Phase 3Active
- Sponsor
- Akeso, Inc.
- Start
- May 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ivonescimab in colorectal adenocarcinoma, sponsored by Akeso, Inc.. Started May 2025; status: active.
02
Drugs
ivonescimab
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on CTR20250877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250877.